ClinicalTrials.gg
CompletedNCT02749994I-ROSETTEUpdated Jun 13, 2018

A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

A Phase 3 interventional study of Rosuvastatin and Ezetimibe in Hypercholesterolemia, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
22nd of 97
396 · median 148
Started
2016
with 3 others
Phase 3
50 of 98
1 open now
Registered
76th of 98
by date
Lead sponsor
2 of 98
IlDong Pharmaceutical Co Ltd

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 22nd largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2016, is one of 50 in phase 3, and was the 76th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

A phase Ⅲ, multi-center, randomized, double-blinded, active comparator, factorial design clinical trial to compare the efficacy and safety of a combination therapy of ezetimibe and rosuvastatin versus monotherapy of rosuvastatin in hypercholesterolemia patients.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 \~ 79 years old
  2. Patients who confirmed hypercholesterolemia.
  3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Visit2.
  4. Patients with Triglyceride\< 400 at Visit 2.
  5. Patients who have a over 4 weeks for other drugs that can affect lipid profile.(Patients who have lipid regulators should have washout period over six weeks)
  6. Patients who agreed to participate in the trial

Exclusion criteria

Exclusion Criteria:

  1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase inhibitors) or ezetimibe.
  2. A heavy alcohol consumer. (alcohol > 25 units/week)
  3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)
  4. Patients with active liver disease and (aspartate transaminase) or ALT(alanine transaminase) > 2 times of .
  5. Patients with CPK(creatine phosphokinase) > 2 x upper limit of normal range.
  6. Patients who have a endocrine or metabolic diseases known to affect the serum phospholipid or lipoprotein.
  7. Patients with (human immunodeficiency virus positive.
  8. Patients who have a acute arteriopathy.
  9. Patients with uncontrolled hypertension.
  10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  11. Patients who have a drugs absorption disorder by gastrointestinal surgery or gastrointestinal disorder.
  12. Patients with tumor.
  13. Patients who have hormonal therapy.
  14. Pregnancy or breastfeeding patients who don't agree to use adequate .
  15. Patients who are judged unsuitable to participate in this study by investigator.
  16. Patients taking other clinical trial drugs within 30 days from the time of visit for screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Active comparator
    R5

    Rosuvastatin 5mg

    Drug: Rosuvastatin

  • Active comparator
    R10

    Rosuvastatin 10mg

    Drug: Rosuvastatin

  • Active comparator
    R20

    Rosuvastatin 20mg

    Drug: Rosuvastatin

  • Experimental
    R5/E10

    Rosuvastatin 5mg/Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

  • Experimental
    R10/E10

    Rosuvastatin 10mg/Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

  • Experimental
    R20/E10

    Rosuvastatin 20mg/Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 8 week in LDL-Cholesterol

    Time frame: baseline and 8 week

Secondary outcomes

  1. Percent change from baseline to 4 and 8 week in Total Cholesterol

    Time frame: baseline to 4 and 8 week

  2. Percent change from baseline to 4 and 8 week in Triglyceride

    Time frame: baseline to 4 and 8 week

  3. Percent change from baseline to 4 and 8 week in HDL-Cholesterol

    Time frame: baseline to 4 and 8 week

  4. Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol

    Time frame: baseline to 4 and 8 week

  5. Percent change from baseline to 4 and 8 week in Apolipoprotein B

    Time frame: baseline to 4 and 8 week

  6. Percent change from baseline to 4 and 8 week in Apolipoprotein A1

    Time frame: baseline to 4 and 8 week

  7. Percent change from baseline to 4 week in LDL-Cholesterol

    Time frame: baseline to 4 week

  8. Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)

    Time frame: baseline to 4 and 8

  9. The change of LDL-Cholesterol/HDL-Cholesterol ratio

    Time frame: baseline to 4 and 8 week

  10. The change of Total Cholesterol/HDL-Cholesterol ratio

    Time frame: baseline to 4 and 8 week

  11. The change of non-HDL-Cholesterol/HDL-Cholesterol ratio

    Time frame: baseline to 4 and 8 week

  12. The change of Apolipoprotein B/Apolipoprotein A1 ratio

    Time frame: baseline to 4 and 8 week

  13. The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline

    Time frame: baseline to 4 and 8 week

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, Cho SK, Kim SY, Yoo BS, Sung KC, Rha SW, Shin JH, Han KR, Chung WS, Hyon MS, Lee HC, Bae JH, Rhee MY, Kwan J, Jeon DW, Yoo KD, Kim HS. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018 Feb;40(2):226-241.e4. doi: 10.1016/j.clinthera.2017.12.018. PubMed 29402522 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2016
First posted
Apr 25, 2016
Start
Apr 2016
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02749994
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Apr 2016
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Jun 13, 2018

Study contacts

Hyo-soo Kim, MD/PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion